12/12
01:39 pm
bmy
Is Bristol-Myers Squibb a Value Opportunity After 5.1% Rebound and DCF Outlook? [Yahoo! Finance]
Low
Report
Is Bristol-Myers Squibb a Value Opportunity After 5.1% Rebound and DCF Outlook? [Yahoo! Finance]
12/12
09:12 am
bmy
Bristol Myers Squibb (NYSE:BMY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Bristol Myers Squibb (NYSE:BMY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
12/12
06:54 am
bmy
Quebec becomes first province in Canada to list new subcutaneous OPDIVO® on public drug plan for solid tumour indications [Yahoo! Finance]
Low
Report
Quebec becomes first province in Canada to list new subcutaneous OPDIVO® on public drug plan for solid tumour indications [Yahoo! Finance]
12/12
04:39 am
bmy
How the Narrative Surrounding Bristol Myers Squibb Is Shifting After Recent Sector and Policy Updates [Yahoo! Finance]
Low
Report
How the Narrative Surrounding Bristol Myers Squibb Is Shifting After Recent Sector and Policy Updates [Yahoo! Finance]
12/11
06:37 pm
bmy
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript [Seeking Alpha]
Low
Report
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript [Seeking Alpha]
12/11
12:59 pm
bmy
Fusion Proteins Market to Hit $64.9 Billion by 2030 [Yahoo! Finance]
Low
Report
Fusion Proteins Market to Hit $64.9 Billion by 2030 [Yahoo! Finance]
12/11
12:13 pm
bmy
Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035 [Yahoo! Finance]
Low
Report
Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035 [Yahoo! Finance]
12/11
07:48 am
bmy
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma [Yahoo! Finance]
Low
Report
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma [Yahoo! Finance]
12/11
06:59 am
bmy
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
Low
Report
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
12/10
04:27 pm
bmy
Bristol-Myers Squibb Company raises dividend by 1.6% [Seeking Alpha]
Low
Report
Bristol-Myers Squibb Company raises dividend by 1.6% [Seeking Alpha]
12/10
04:16 pm
bmy
Bristol Myers Squibb Announces Dividend Increase
Low
Report
Bristol Myers Squibb Announces Dividend Increase
12/10
03:23 pm
bmy
Bristol Myers Squibb (NYSE:BMY) had its price target raised by analysts at Wells Fargo & Company from $53.00 to $55.00. They now have an "equal weight" rating on the stock.
Low
Report
Bristol Myers Squibb (NYSE:BMY) had its price target raised by analysts at Wells Fargo & Company from $53.00 to $55.00. They now have an "equal weight" rating on the stock.
12/10
11:40 am
bmy
Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY) [Yahoo! Finance]
Low
Report
Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY) [Yahoo! Finance]
12/10
07:21 am
bmy
Bristol Myers Squibb (NYSE:BMY) had its "hold" rating reaffirmed by analysts at HSBC Holdings plc.
Low
Report
Bristol Myers Squibb (NYSE:BMY) had its "hold" rating reaffirmed by analysts at HSBC Holdings plc.
12/9
07:36 pm
bmy
Bristol Myers Squibb (BMY): Revisiting Valuation After a Recent Share Price Rebound [Yahoo! Finance]
Low
Report
Bristol Myers Squibb (BMY): Revisiting Valuation After a Recent Share Price Rebound [Yahoo! Finance]
12/9
05:56 pm
bmy
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart [Seeking Alpha]
Low
Report
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart [Seeking Alpha]
12/8
04:30 pm
bmy
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
Low
Report
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
12/6
12:59 am
bmy
Jim Cramer on Bristol-Myers' Recent Stock Gain: “Unbelievable” [Yahoo! Finance]
Low
Report
Jim Cramer on Bristol-Myers' Recent Stock Gain: “Unbelievable” [Yahoo! Finance]
12/4
08:53 pm
bmy
Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) [Yahoo! Finance]
Low
Report
Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) [Yahoo! Finance]
12/4
08:15 pm
bmy
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Low
Report
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
12/4
08:45 am
bmy
Bristol Myers Squibb (NYSE:BMY) had its "sector perform" rating reaffirmed by analysts at Scotiabank.
Low
Report
Bristol Myers Squibb (NYSE:BMY) had its "sector perform" rating reaffirmed by analysts at Scotiabank.
12/4
12:08 am
bmy
How faster decisions can transform patient care in Canada [Globe and Mail, The (Toronto, Canada)]
Low
Report
How faster decisions can transform patient care in Canada [Globe and Mail, The (Toronto, Canada)]
12/3
04:14 pm
bmy
Bristol Myers Squibb (NYSE:BMY) was given a new $65.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Bristol Myers Squibb (NYSE:BMY) was given a new $65.00 price target on by analysts at Truist Financial Corporation.
12/3
11:00 am
bmy
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
Low
Report
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
12/3
06:59 am
bmy
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
Medium
Report
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease